

# Henning Grnbk

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1915941/henning-gronbaek-publications-by-year.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

266 papers	8,554 citations	45 h-index	84 g-index
299 ext. papers	11,494 ext. citations	4.5 avg, IF	5.98 L-index

#	Paper	IF	Citations
266	Macrophage activation marker sCD163 is associated with liver injury and hepatic insulin resistance in obese patients before and after Roux-en-Y gastric bypass.. <i>Physiological Reports</i> , <b>2022</b> , 10, e15157	2.6	0
265	The galactose elimination capacity test to monitor liver disease course in patients with Wilson's disease.. <i>Scandinavian Journal of Gastroenterology</i> , <b>2022</b> , 1-6	2.4	
264	Non-alcoholic fatty liver disease in patients with type 2 diabetes in Greenland: a register-based cross-sectional study.. <i>International Journal of Circumpolar Health</i> , <b>2022</b> , 81, 2065755	1.7	1
263	Effects and safety of natriuretic peptides as treatment of cirrhotic ascites: A systematic review and meta-analysis. <i>World Journal of Hepatology</i> , <b>2022</b> , 14, 827-845	3.4	
262	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2021</b> ,	24.2	37
261	The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNF $\alpha$ Treatment in Crohn's Disease. <i>Journal of Clinical Gastroenterology</i> , <b>2021</b> , 55, 59-66	3	4
260	A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations. <i>Neuroendocrinology</i> , <b>2021</b> , 111, 883-894	5.6	25
259	A Plasma Protein Biomarker Strategy for Detection of Small Intestinal Neuroendocrine Tumors. <i>Neuroendocrinology</i> , <b>2021</b> , 111, 840-849	5.6	3
258	Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis. <i>Clinical and Translational Gastroenterology</i> , <b>2021</b> , 12, e00315	4.2	4
257	Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma. <i>BMC Cancer</i> , <b>2021</b> , 21, 376	4.8	3
256	Core liver homeostatic co-expression networks are preserved but respond to perturbations in an organism- and disease-specific manner. <i>Cell Systems</i> , <b>2021</b> , 12, 432-445.e7	10.6	1
255	Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. <i>Acta Oncologica</i> , <b>2021</b> , 60, 931-941	3.2	6
254	P316 Human neutrophil elastase derived fragment of calprotectin (S100a9) is a serum biomarker (CPa9-HNE) for monitoring of anti-TNF $\alpha$ treatment response in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, S342-S343	1.5	
253	Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 320-328	6.1	1
252	Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement. <i>Hepatology</i> , <b>2021</b> , 74, 474-482	11.2	16
251	Metabolic effects of 1-week binge drinking and fast food intake during Roskilde Festival in young healthy male adults. <i>European Journal of Endocrinology</i> , <b>2021</b> , 185, 23-32	6.5	0
250	Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute-on-chronic liver failure and acute decompensation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2021</b> , 36, 240-248	4	8

249	Altered balance between collagen formation and degradation after successful direct-acting antiviral therapy of chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 236-244	3.4	1
248	Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2021</b> , 15, 51-64	4.2	3
247	Clinical efficacy of first and second series of peptide receptor radionuclide therapy in patients with neuroendocrine neoplasm: a cohort study. <i>Scandinavian Journal of Gastroenterology</i> , <b>2021</b> , 56, 289-297	2.4	4
246	CELL-FREE DNA AND CLINICAL CHARACTERISTICS IN PATIENTS WITH SMALL INTESTINAL OR PANCREATIC NEUROENDOCRINE TUMORS. <i>Neuroendocrinology</i> , <b>2021</b> ,	5.6	2
245	No Effect in Alcoholic Hepatitis of Gut-Selective, Broad-Spectrum Antibiotics on Bacterial Translocation or Hepatic and Systemic Inflammation. <i>Clinical and Translational Gastroenterology</i> , <b>2021</b> , 12, e00306	4.2	2
244	Interferon lambda 4 genotype and pathway in alcoholic hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2021</b> , 56, 304-311	2.4	
243	Efficacy of Dietary Manipulations for Depleting Intrahepatic Triglyceride Content: Implications for the Management of Non-alcoholic Fatty Liver Disease. <i>Current Obesity Reports</i> , <b>2021</b> , 10, 125-133	8.4	4
242	A randomised, factorial phase II study to determine the optimal dosing regimen for Ga-satoreotide trizoxetan as an imaging agent in patients with gastroenteropancreatic neuroendocrine tumours. <i>Journal of Nuclear Medicine</i> , <b>2021</b> ,	8.9	3
241	Metformin Stimulates Intestinal Glycolysis and Lactate Release: A single-Dose Study of Metformin in Patients With Intrahepatic Portosystemic Stent. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 1329-1336	6.1	0
240	Cognitive impairment in stable Wilson disease across phenotype. <i>Metabolic Brain Disease</i> , <b>2021</b> , 36, 2173-2177	3.9	0
239	A novel read methodology to evaluate the optimal dose of Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial. <i>EJNMMI Research</i> , <b>2021</b> , 11, 84	3.6	1
238	Increased occurrence of liver and gastrointestinal diseases and anaemia in women with Turner syndrome - a nationwide cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 821-829	6.1	1
237	Extracellular vesicle-associated soluble CD163 and CD206 in patients with acute and chronic inflammatory liver disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2020</b> , 55, 588-596	2.4	4
236	Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure. <i>Cells</i> , <b>2020</b> , 9,	7.9	30
235	Soluble PD1 levels are increased with disease activity in paediatric onset autoimmune hepatitis and inflammatory bowel disease. <i>Autoimmunity</i> , <b>2020</b> , 53, 253-260	3	2
234	The effect of acute intragastric vs. intravenous alcohol administration on inflammation markers, blood lipids and gallbladder motility in healthy men. <i>Alcohol</i> , <b>2020</b> , 87, 29-37	2.7	1
233	Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial. <i>BMJ Open</i> , <b>2020</b> , 10, e035284	3	3
232	Fibrogenesis and inflammation contribute to the pathogenesis of cirrhotic cardiomyopathy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 340-350	6.1	7

231	Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. <i>BMC Gastroenterology</i> , <b>2020</b> , 20, 210	3	9
230	The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's disease. <i>Orphanet Journal of Rare Diseases</i> , <b>2020</b> , 15, 173	4.2	4
229	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , <b>2020</b> , 158, 1999-2014.e1	13.3	748
228	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 202-209	13.4	764
227	The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease. <i>Trends in Genetics</i> , <b>2020</b> , 36, 429-441	8.5	28
226	Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis. <i>Liver International</i> , <b>2020</b> , 40, 1408-1414	7.9	13
225	PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3. <i>PLoS ONE</i> , <b>2020</b> , 15, e0243900	3.7	5
224	SAT-025 Increased Occurrence of Anemia, Gastrointestinal and Liver Diseases in Women with Turner Syndrome - a Nationwide Registry Study. <i>Journal of the Endocrine Society</i> , <b>2020</b> , 4,	0.4	78
223	Liver-related effects of chronic hepatitis C antiviral treatment. <i>World Journal of Gastroenterology</i> , <b>2020</b> , 26, 2931-2947	5.6	5
222	New tight junction protein 2 variant causing progressive familial intrahepatic cholestasis type 4 in adults: A case report. <i>World Journal of Gastroenterology</i> , <b>2020</b> , 26, 550-561	5.6	10
221	Time-dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 28-35	3.4	25
220	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 688-701	13.4	102
219	Thrombophilia testing in patients with portal vein thrombosis. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2020</b> , 80, 694-698	2	3
218	One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	2
217	Macrophage markers and innate immunity in cirrhosis. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1586-1588	13.4	6
216	Contrast-enhanced ultrasound compared with computed tomography, magnetic resonance imaging, and positron emission tomography-computed tomography for diagnosing liver metastases in people with newly diagnosed colorectal cancer. <i>The Cochrane Library</i> , <b>2020</b> ,	5.2	78
215	Serological Biomarkers of Tissue Turnover Identify Responders to Anti-TNF Therapy in Crohn's Disease: A Pilot Study. <i>Clinical and Translational Gastroenterology</i> , <b>2020</b> , 11, e00217	4.2	1
214	TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , <b>2020</b> , 55, 1433-1440	2.4	14

213	Early normalization of reduced urea synthesis capacity after direct-acting antiviral therapy in hepatitis C cirrhosis. <i>American Journal of Physiology - Renal Physiology</i> , <b>2020</b> , 319, G151-G156	5.1	1
212	Letter: improve survival! Place early pre-emptive TIPSS in high-risk variceal bleeders. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 927-928	6.1	4
211	Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 616212	4.9	1
210	Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors. <i>Neuroendocrinology</i> , <b>2020</b> , 110, 217-224	5.6	12
209	Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 963-973.e14	6.9	38
208	Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 615599	4.9	6
207	The macrophage-related biomarkers sCD163 and sCD206 are released by different shedding mechanisms. <i>Journal of Leukocyte Biology</i> , <b>2019</b> , 106, 1129-1138	6.5	19
206	Non-alcoholic steatohepatitis, but not simple steatosis, disturbs the functional homogeneity of the liver - a human galactose positron emission tomography study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 84-92	6.1	4
205	Macrophage markers soluble CD163 and soluble mannose receptor are associated with liver injury in patients with paracetamol overdose. <i>Scandinavian Journal of Gastroenterology</i> , <b>2019</b> , 54, 623-632	2.4	5
204	Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects. <i>World Journal of Hepatology</i> , <b>2019</b> , 11, 138-149	3.4	75
203	Hepatic exposure of metformin in patients with non-alcoholic fatty liver disease. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 1761-1770	3.8	9
202	Preemptive-TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study. <i>Hepatology</i> , <b>2019</b> , 69, 282-293	11.2	73
201	Soluble CD163 correlates with lipid metabolic adaptations in type 1 diabetes patients during ketoacidosis. <i>Journal of Diabetes Investigation</i> , <b>2019</b> , 10, 67-72	3.9	2
200	The role of IFN in the development of NAFLD and NASH. <i>Cytokine</i> , <b>2019</b> , 124, 154519	4	17
199	FRI-016-Validation of the PRETo machine learning algorithm for the prediction of disease progression in patients with primary sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e390-e391	13.4	2
198	Use of biologically based complementary medicines in patients with neuroendocrine tumors. <i>Scandinavian Journal of Gastroenterology</i> , <b>2019</b> , 54, 998-1002	2.4	
197	Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 1012-1021	13.4	66
196	Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial. <i>EBioMedicine</i> , <b>2019</b> , 46, 444-451	8.8	8

195	P282 Combination of biomarkers reflecting type IV collagen degradation and citrullinated vimentin predicts response to adalimumab with high diagnostic accuracy, in patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S239-S240	1.5	
194	Effects of implementation of a national fast track clinical pathway for hepatocellular carcinoma in Western Denmark. <i>Journal of Gastrointestinal and Liver Diseases</i> , <b>2019</b> , 28, 83-88	1.4	2
193	Non-alcoholic fatty liver disease causes dissociated changes in metabolic liver functions. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2019</b> , 43, 551-560	2.4	20
192	The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2019</b> , 16, 145-159	24.2	284
191	Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. <i>American Journal of Physiology - Renal Physiology</i> , <b>2019</b> , 316, G462-G472	5.1	63
190	The insulin-like growth factor family and breast cancer prognosis: A prospective cohort study among postmenopausal women in Denmark. <i>Growth Hormone and IGF Research</i> , <b>2019</b> , 44, 33-42	2	7
189	Orchestration of Tryptophan-Kynurenine Pathway, Acute Decompensation, and Acute-on-Chronic Liver Failure in Cirrhosis. <i>Hepatology</i> , <b>2019</b> , 69, 1686-1701	11.2	45
188	The Macrophage Activation Marker Soluble CD163 is Associated With Early Allograft Dysfunction After Liver Transplantation. <i>Journal of Clinical and Experimental Hepatology</i> , <b>2019</b> , 9, 302-311	4.1	3
187	Adult Presentation of Noncirrhotic Portal Hypertension and Ascites following Treatment for Wilms' Tumor in Childhood. <i>Case Reports in Gastroenterology</i> , <b>2018</b> , 12, 56-62	1	2
186	Nutritional status and nutritional risk in patients with neuroendocrine tumors. <i>Scandinavian Journal of Gastroenterology</i> , <b>2018</b> , 53, 284-292	2.4	17
185	Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 657-664	6.1	32
184	Unexplained cholestasis in adults and adolescents: diagnostic benefit of genetic examination. <i>Scandinavian Journal of Gastroenterology</i> , <b>2018</b> , 53, 305-311	2.4	10
183	Macrophage activation marker sCD163 correlates with accelerated lipolysis following LPS exposure: a human-randomised clinical trial. <i>Endocrine Connections</i> , <b>2018</b> , 7, 107-114	3.5	10
182	Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). <i>Medical Oncology</i> , <b>2018</b> , 35, 47	3.7	7
181	Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 484-491	4	22
180	Cell death markers in patients with cirrhosis and acute decompensation. <i>Hepatology</i> , <b>2018</b> , 67, 989-1002	11.2	49
179	βBlockers Improve Presinusoidal Portal Hypertension. <i>Digestive Diseases and Sciences</i> , <b>2018</b> , 63, 3153-3157		6
178	Urea cycle dysregulation in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 905-915	13.4	66



177	Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology. <i>Scandinavian Journal of Gastroenterology</i> , <b>2018</b> , 53, 986-993	3.4	15
176	The Risk of Second Primary Colorectal Adenocarcinomas Is Not Increased among Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Nationwide Population-Based Study. <i>Neuroendocrinology</i> , <b>2018</b> , 107, 280-283	5.6	1
175	No effect of resveratrol on VLDL-TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2504-2509	6.7	15
174	Niemann-Pick type C2 protein supplementation in experimental non-alcoholic fatty liver disease. <i>PLoS ONE</i> , <b>2018</b> , 13, e0192728	3.7	6
173	Preserved liver regeneration capacity after partial hepatectomy in rats with non-alcoholic steatohepatitis. <i>World Journal of Hepatology</i> , <b>2018</b> , 10, 8-21	3.4	9
172	Effects of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Goblet Cell Carcinoma: A Prospective Cohort Study. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 422-430	3.1	14
171	Time course of compromised urea synthesis in patients with alcoholic hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2018</b> , 53, 592-597	2.4	4
170	P196 Serum biomarkers reflecting tissue-remodelling correlates with the simple endoscopic score for Crohn's disease. <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, S197-S197	1.5	
169	Macrophage Markers Are Poorly Associated With Liver Histology in Children With Nonalcoholic Fatty Liver Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2018</b> , 67, 635-642	2.8	6
168	High hepatic macrophage activation and low liver function in stable Wilson patients - a Danish cross-sectional study. <i>Orphanet Journal of Rare Diseases</i> , <b>2018</b> , 13, 169	4.2	6
167	No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial. <i>PLoS ONE</i> , <b>2018</b> , 13, e0203200	3.7	4
166	Albumin administration in the prevention of hepatorenal syndrome (HRS) and death in patients with advanced cirrhosis and non-SBP infections. <i>Journal of Hepatology</i> , <b>2018</b> , 68, S253-S254	13.4	4
165	Antibody-Directed Glucocorticoid Targeting to CD163 in M2-type Macrophages Attenuates Fructose-Induced Liver Inflammatory Changes. <i>Molecular Therapy - Methods and Clinical Development</i> , <b>2017</b> , 4, 50-61	6.4	40
164	Long-Term Ethanol Exposure Decreases the Endotoxin-Induced Hepatic Acute Phase Response in Rats. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2017</b> , 41, 562-570	3.7	2
163	IFN- $\beta$ , not IFN- $\alpha$ , likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. <i>Nature Genetics</i> , <b>2017</b> , 49, 795-800	36.3	72
162	Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. <i>European Journal of Surgical Oncology</i> , <b>2017</b> , 43, 1682-1689	3.6	31
161	A germline mutation is associated with small intestinal neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , <b>2017</b> , 24, 427-443	5.7	33
160	Enrichment of Genetic Variants in the Glucocorticoid Receptor Signalling Pathway in Autoimmune Hepatitis with Failure of Standard Treatment. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2017</b> , 121, 189-194	3.1	4

159	Men with biopsy-confirmed hepatocellular adenoma have a high risk of progression to hepatocellular carcinoma: A nationwide population-based study. <i>Liver International</i> , <b>2017</b> , 37, 1042-1046	7.9	18
158	Circulating sCD36 levels in patients with non-alcoholic fatty liver disease and controls. <i>International Journal of Obesity</i> , <b>2017</b> , 41, 262-267	5.5	16
157	A descriptive cross-sectional study of pain in patients with neuroendocrine tumors. <i>Scandinavian Journal of Gastroenterology</i> , <b>2017</b> , 52, 431-436	2.4	1
156	Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. <i>Lancet Oncology</i> , <b>2017</b> , 18, 1652-1664	21.7	70
155	The soluble mannose receptor (sMR) is elevated in alcoholic liver disease and associated with disease severity, portal hypertension, and mortality in cirrhosis patients. <i>PLoS ONE</i> , <b>2017</b> , 12, e0189345	3.7	25
154	Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2017</b> , 77, 498-504	2	13
153	Letter: autoimmune hepatitis-drug-induced liver injury must always be excluded. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 384	6.1	0
152	Isolated congenital hepatic fibrosis associated with mutations: report of a new genotype-phenotype relationship. <i>Clinical Case Reports (discontinued)</i> , <b>2017</b> , 5, 1098-1102	0.7	5
151	Wet Biomarker-Based Assessment of Steatosis, Inflammation, and Fibrosis in NAFLD. <i>Current Hepatology Reports</i> , <b>2017</b> , 16, 308-316	1	
150	High burden of coronary atherosclerosis in patients with cirrhosis. <i>European Journal of Clinical Investigation</i> , <b>2017</b> , 47, 565-573	4.6	10
149	Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. <i>Liver International</i> , <b>2017</b> , 37, 694-699	7.9	128
148	Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2017</b> , 52, 93-99	2.4	27
147	The soluble mannose receptor is released from the liver in cirrhotic patients, but is not associated with bacterial translocation. <i>Liver International</i> , <b>2017</b> , 37, 569-575	7.9	11
146	Methotrexate Use and Monitoring in Patients with Psoriasis: A Consensus Report Based on a Danish Expert Meeting. <i>Acta Dermato-Venereologica</i> , <b>2017</b> , 97, 426-432	2.2	26
145	Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. <i>PLoS ONE</i> , <b>2017</b> , 12, e0187667	3.7	16
144	Soluble CD163 (sCD163): Biomarker of Kupffer Cell Activation in Liver Disease. <i>Biomarkers in Disease</i> , <b>2017</b> , 321-348		1
143	Protonenpumpenhemmer bei Leberzirrhose: Einfluss auf Dysbiose, Darmpermeabilität, Inflammation und Mortalität. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2017</b> , 55, e28-e56	1.6	
142	Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art. <i>Acta Oncologica</i> , <b>2016</b> , 55, 3-14	3.2	9



141	Fibrosis is not just fibrosis - basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 1242-1252	6.1	25
140	MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. <i>Nature Communications</i> , <b>2016</b> , 7, 12757	17.4	73
139	Single-centre experience of the macrophage activation marker soluble (s)CD163 - associations with disease activity and treatment response in patients with autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 1062-1070	6.1	25
138	Contrast-enhanced ultrasound compared with computed tomography, magnetic resonance imaging, and positron emission tomography for diagnosing liver metastases in people with newly diagnosed colorectal cancer. <i>The Cochrane Library</i> , <b>2016</b> ,	5.2	1
137	The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , <b>2016</b> , 36, 1549-57	7.9	67
136	Combination of radiofrequency ablation with transarterial chemoembolization for treatment of hepatocellular carcinoma: experience from a Danish tertiary liver center. <i>Acta Radiologica</i> , <b>2016</b> , 57, 844-51	2.51	4
135	Reduced sCD36 following weight loss corresponds to improved insulin sensitivity, dyslipidemia and liver fat in obese children. <i>European Journal of Clinical Nutrition</i> , <b>2016</b> , 70, 1073-7	5.2	8
134	Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2016</b> , 51, 456-64	2.4	86
133	Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF). <i>Journal of Hepatology</i> , <b>2016</b> , 64, 813-22	13.4	72
132	Impaired Insulin Suppression of VLDL-Triglyceride Kinetics in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 1637-46	5.6	18
131	Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 1721-8	3.1	59
130	Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2016</b> , 76, 64-73	2	18
129	Alcoholic Hepatitis Markedly Decreases the Capacity for Urea Synthesis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0158388	3.7	9
128	Anti-CD163-dexamethasone conjugate inhibits the acute phase response to lipopolysaccharide in rats. <i>World Journal of Hepatology</i> , <b>2016</b> , 8, 726-30	3.4	14
127	Soluble CD163 (sCD163): Biomarker of Kupffer Cell Activation in Liver Disease. <i>Biomarkers in Disease</i> , <b>2016</b> , 1-28		2
126	Rectal Mechano-sensory Function in Patients with Carcinoid Diarrhea. <i>Journal of Neurogastroenterology and Motility</i> , <b>2016</b> , 22, 264-71	4.4	4
125	Effect of resveratrol on experimental non-alcoholic fatty liver disease depends on severity of pathology and timing of treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 668-75	4	13
124	The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 1222-31	6.1	24

123	The damage-associated molecular pattern HMGB1 is elevated in human alcoholic hepatitis, but does not seem to be a primary driver of inflammation. <i>Apmis</i> , <b>2016</b> , 124, 741-7	3.4	13
122	Urinary aquaporin-2 excretion before and after transjugular intrahepatic portosystemic shunt insertion for refractory ascites. <i>Scandinavian Journal of Gastroenterology</i> , <b>2015</b> , 50, 454-61	2.4	3
121	The Circulating IGF System in Hepatocellular Carcinoma: The Impact of Liver Status and Treatment. <i>Growth Hormone and IGF Research</i> , <b>2015</b> , 25, 174-81	2	15
120	Effect of resveratrol on experimental non-alcoholic steatohepatitis. <i>Pharmacological Research</i> , <b>2015</b> , 95-96, 34-41	10.2	30
119	Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 1293-300	4	43
118	The macrophage activation marker sCD163 is associated with changes in NAFLD and metabolic profile during lifestyle intervention in obese children. <i>Pediatric Obesity</i> , <b>2015</b> , 10, 226-33	4.6	42
117	Circulating mannan-binding lectin, M-, L-, H-ficolin and collectin-liver-1 levels in patients with acute liver failure. <i>Liver International</i> , <b>2015</b> , 35, 756-63	7.9	16
116	Reply: To PMID 24623375. <i>Hepatology</i> , <b>2015</b> , 61, 735-6	11.2	4
115	Goblet cell carcinoids: characteristics of a Danish cohort of 83 patients. <i>PLoS ONE</i> , <b>2015</b> , 10, e0117627	3.7	15
114	Monitoring Kidney Function in Neuroendocrine Tumor Patients Treated with (90)Y-DOTATOC: Associations with Risk Factors. <i>Current Radiopharmaceuticals</i> , <b>2015</b> , 8, 49-55	1.8	8
113	Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients. <i>PLoS ONE</i> , <b>2015</b> , 10, e0137302	3.7	46
112	Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. <i>Acta Oncologica</i> , <b>2014</b> , 53, 1284-97	3.2	87
111	Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF- $\alpha$ antibody treatment in active inflammatory bowel disease. <i>Scandinavian Journal of Immunology</i> , <b>2014</b> , 80, 417-23	3.4	23
110	Experimental nonalcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function. <i>American Journal of Physiology - Renal Physiology</i> , <b>2014</b> , 307, G295-301	5.1	34
109	Hepatic macrophage activation and the LPS pathway in patients with alcoholic hepatitis: a prospective cohort study. <i>American Journal of Gastroenterology</i> , <b>2014</b> , 109, 1749-56	0.7	65
108	Chemoembolization of intermediate stage hepatocellular carcinomas: results from a Nordic tertiary liver cancer center. <i>Indian Journal of Gastroenterology</i> , <b>2014</b> , 33, 322-9	1.9	5
107	Effects of long-acting somatostatin analogues on redox systems in rat lens in experimental diabetes. <i>International Journal of Experimental Pathology</i> , <b>2014</b> , 95, 95-100	2.8	
106	Trefoil factors in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 3223-30	5.6	61

105	Vitamin B <sub>12</sub> and its binding proteins in hepatocellular carcinoma and chronic liver diseases. <i>Scandinavian Journal of Gastroenterology</i> , <b>2014</b> , 49, 1096-102	2.4	17
104	Non-alcoholic steatohepatitis weakens the acute phase response to endotoxin in rats. <i>Liver International</i> , <b>2014</b> , 34, 1584-92	7.9	8
103	Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. <i>Hepatology</i> , <b>2014</b> , 60, 521-30	11.2	115
102	Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , <b>2014</b> , 6, 188-98	3.4	42
101	Prednisolone but not infliximab aggravates the upregulated hepatic nitrogen elimination in patients with active inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , <b>2014</b> , 20, 7-13	4.5	7
100	A comparison of three chromogranin A assays in patients with neuroendocrine tumours. <i>Journal of Gastrointestinal and Liver Diseases</i> , <b>2014</b> , 23, 419-24	1.4	8
99	Quantitative histological assessment of hepatic ischemia-reperfusion injuries following ischemic pre- and post-conditioning in the rat liver. <i>Journal of Surgical Research</i> , <b>2013</b> , 180, e11-20	2.5	15
98	Propranolol treatment of portal hypertension in cirrhosis patients is better the higher the untreated pressure: a single-centre prospective experience. <i>Scandinavian Journal of Gastroenterology</i> , <b>2013</b> , 48, 969-73	2.4	6
97	Regulation of urea synthesis during the acute-phase response in rats. <i>American Journal of Physiology - Renal Physiology</i> , <b>2013</b> , 304, G680-6	5.1	11
96	No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion. <i>Liver International</i> , <b>2013</b> , 33, 1309-15	7.9	17
95	Elevated platelet expression of CD36 may contribute to increased risk of thrombo-embolism in active inflammatory bowel disease. <i>Archives of Physiology and Biochemistry</i> , <b>2013</b> , 119, 202-8	2.2	6
94	Hepatic macrophage activation predicts clinical decompensation in chronic liver disease. <i>Gut</i> , <b>2013</b> , 62, 1231-2	19.2	34
93	Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. <i>Annals of Oncology</i> , <b>2013</b> , 24, 152-60	10.3	598
92	Highest frequencies of interleukin-22-producing T helper cells in alcoholic hepatitis patients with a favourable short-term course. <i>PLoS ONE</i> , <b>2013</b> , 8, e55101	3.7	24
91	Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability. <i>Scientific World Journal, The</i> , <b>2013</b> , 2013, 931972	2.2	19
90	Goblet cell carcinoids of the appendix. <i>Scientific World Journal, The</i> , <b>2013</b> , 2013, 543696	2.2	29
89	Treatment of Budd-Chiari syndrome with a focus on transjugular intrahepatic portosystemic shunt. <i>World Journal of Hepatology</i> , <b>2013</b> , 5, 38-42	3.4	14
88	Effects of long-term experimental diabetes on adrenal gland growth and phosphoribosyl pyrophosphate formation in growth hormone-deficient dwarf rats. <i>International Journal of Experimental Pathology</i> , <b>2012</b> , 93, 196-201	2.8	2

87	Cirrhosis and mortality risks of biopsy-verified alcoholic pure steatosis and steatohepatitis: a nationwide registry-based study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 1336-42	6.1	44
86	Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 173-80	6.1	109
85	Gender and age effects on the continuous reaction times method in volunteers and patients with cirrhosis. <i>Metabolic Brain Disease</i> , <b>2012</b> , 27, 559-65	3.9	25
84	Changes in adipokines after transjugular intrahepatic porto-systemic shunt indicate an anabolic shift in metabolism. <i>Clinical Nutrition</i> , <b>2012</b> , 31, 940-5	5.9	13
83	Carvedilol or propranolol in portal hypertension? A randomized comparison. <i>Scandinavian Journal of Gastroenterology</i> , <b>2012</b> , 47, 467-74	2.4	40
82	Ischemic pre- and postconditioning has pronounced effects on gene expression profiles in the rat liver after ischemia/reperfusion. <i>American Journal of Physiology - Renal Physiology</i> , <b>2012</b> , 303, G482-9	5.1	13
81	Small intestinal transit in patients with liver cirrhosis and portal hypertension: a descriptive study. <i>BMC Gastroenterology</i> , <b>2012</b> , 12, 176	3	12
80	Creation of a fistula between the hepatic duct and the gastric lumen by way of percutaneous transhepatic cholangiography: a case report. <i>Journal of Gastrointestinal Cancer</i> , <b>2012</b> , 43, 354-7	1.6	
79	Effects of long-acting somatostatin analogues on adrenal growth and phosphoribosyl pyrophosphate formation in experimental diabetes. <i>International Journal of Experimental Pathology</i> , <b>2012</b> , 93, 56-69	2.8	3
78	Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel(®) given by either self/partner or a health care professional. <i>Patient Preference and Adherence</i> , <b>2012</b> , 6, 703-10	2.4	14
77	Insulin-like growth factor-I concentration and risk of prostate cancer: results from the European Prospective Investigation into Cancer and Nutrition. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2012</b> , 21, 1531-41	4	56
76	Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. <i>British Journal of Cancer</i> , <b>2012</b> , 106, 1004-10	8.7	40
75	Effect of a 10-week weight loss camp on fatty liver disease and insulin sensitivity in obese Danish children. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2012</b> , 54, 223-8	2.8	51
74	Unchanged capacity of urea synthesis during acute phase response in rats. <i>European Journal of Clinical Investigation</i> , <b>2011</b> , 41, 16-22	4.6	2
73	Effects of ischemic pre- and postconditioning on HIF-1 $\alpha$ /VEGF and TGF- $\beta$ expression after warm ischemia and reperfusion in the rat liver. <i>Comparative Hepatology</i> , <b>2011</b> , 10, 3		22
72	A cross-sectional analysis of the associations between adult height, BMI and serum concentrations of IGF-I and IGFBP-1 -2 and -3 in the European Prospective Investigation into Cancer and Nutrition (EPIC). <i>Annals of Human Biology</i> , <b>2011</b> , 38, 194-202	1.7	59
71	Age-dependency of galactose elimination capacity in healthy children and children with chronic liver disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2011</b> , 46, 197-200	2.4	5
70	IL-6 has no acute effect on the regulation of urea synthesis in vivo in rats. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2011</b> , 71, 150-6	2	6

69	Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors. <i>Scandinavian Journal of Gastroenterology</i> , <b>2011</b> , 46, 895-902	2.4	19
68	Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. <i>Gut</i> , <b>2011</b> , 60, 1389-93	19.2	93
67	Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. <i>Neuroendocrinology</i> , <b>2011</b> , 93, 189-96	5.6	105
66	Expression of genes involved in rat liver angiogenesis after ischaemia and reperfusion: effects of ischaemic pre- and post-conditioning. <i>Hpb</i> , <b>2010</b> , 12, 554-60	3.8	9
65	Ascites from patients with alcoholic liver cirrhosis contains higher IGF-I bioactivity than serum. <i>Clinical Endocrinology</i> , <b>2010</b> , 72, 625-32	3.4	17
64	Effect of weight reduction on insulin sensitivity, sex hormone-binding globulin, sex hormones and gonadotrophins in obese children. <i>European Journal of Endocrinology</i> , <b>2010</b> , 163, 895-900	6.5	24
63	Partial liver ischemia is followed by metabolic changes in the normally perfused part of the liver during reperfusion. <i>European Surgical Research</i> , <b>2010</b> , 45, 61-7	1.1	1
62	Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. <i>Acta Oncologica</i> , <b>2010</b> , 49, 740-56	3.2	56
61	Insulin sensitivity and body composition in cirrhosis: changes after TIPS. <i>American Journal of Physiology - Renal Physiology</i> , <b>2010</b> , 299, G486-93	5.1	15
60	Tumor necrosis factor-alpha acutely up-regulates urea synthesis in vivo in rats--a hepatic component of inflammatory catabolism?. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2010</b> , 70, 151-7	2	10
59	Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. <i>International Journal of Cancer</i> , <b>2010</b> , 126, 1702-15	7.5	146
58	Body composition changes after transjugular intrahepatic portosystemic shunt in patients with cirrhosis. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 348-53	5.6	26
57	Soluble membrane attack complex in ascites in patients with liver cirrhosis without infections. <i>World Journal of Hepatology</i> , <b>2010</b> , 2, 221-5	3.4	2
56	Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 96-101	0.7	316
55	Cytokine changes during warm ischemia and reperfusion of the pig liver with or without preconditioning. <i>European Surgical Research</i> , <b>2009</b> , 42, 216-22	1.1	12
54	The IGF system after insertion of a transjugular intrahepatic porto-systemic shunt in patients with liver cirrhosis. <i>European Journal of Endocrinology</i> , <b>2009</b> , 160, 957-63	6.5	15
53	The association between diet and serum concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the European Prospective Investigation into Cancer and Nutrition. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2009</b> , 18, 1333-40	4	103
52	The influence of preconditioning on metabolic changes in the pig liver before, during, and after warm liver ischemia measured by microdialysis. <i>Hepatology International</i> , <b>2009</b> , 3, 310-5	8.8	10

51	Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. <i>Growth Hormone and IGF Research</i> , <b>2009</b> , 19, 426-31	2	3
50	Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2008</b> , 2, 705-11	4.2	29
49	Metabolic changes in the pig liver during warm ischemia and reperfusion measured by microdialysis. <i>Journal of Gastrointestinal Surgery</i> , <b>2008</b> , 12, 319-26	3.3	20
48	Liver cirrhosis, other liver diseases, and risk of hospitalisation for intracerebral haemorrhage: a Danish population-based case-control study. <i>BMC Gastroenterology</i> , <b>2008</b> , 8, 16	3	46
47	Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. <i>International Journal of Cancer</i> , <b>2007</b> , 121, 368-76	7.5	144
46	Effects of urodilatin on natriuresis in cirrhosis patients with sodium retention. <i>BMC Gastroenterology</i> , <b>2007</b> , 7, 1	3	12
45	Diet, serum insulin-like growth factor-I and IGF-binding protein-3 in European women. <i>European Journal of Clinical Nutrition</i> , <b>2007</b> , 61, 91-8	5.2	106
44	Opposite effects on regulation of urea synthesis by early and late uraemia in rats. <i>Clinical Nutrition</i> , <b>2007</b> , 26, 245-51	5.9	5
43	Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2007</b> , 16, 1121-7	4	79
42	Effects of five different alcoholic drinks on patients with Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2007</b> , 42, 968-72	2.4	23
41	The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2007</b> , 42, 464-70	2.4	22
40	Impact of enteral supplements enriched with omega-3 fatty acids and/or omega-6 fatty acids, arginine and ribonucleic acid compounds on leptin levels and nutritional status in active Crohn's disease treated with prednisolone. <i>Digestion</i> , <b>2007</b> , 75, 10-6	3.6	14
39	The insulin-like growth factor (IGF)-system in active ulcerative colitis and Crohn's disease: relations to disease activity and corticosteroid treatment. <i>Growth Hormone and IGF Research</i> , <b>2007</b> , 17, 33-40	2	23
38	Soluble CD163 from activated macrophages predicts mortality in acute liver failure. <i>Journal of Hepatology</i> , <b>2007</b> , 47, 671-6	13.4	124
37	Serum trefoil factors in patients with inflammatory bowel disease. <i>Digestion</i> , <b>2006</b> , 74, 33-9	3.6	36
36	Discharge diagnoses of liver diseases in Nuuk Greenland compared to a Danish county hospital. <i>International Journal of Circumpolar Health</i> , <b>2006</b> , 65, 162-8	1.7	6
35	Associations between the IGF system and inflammatory markers in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 23, 553-4; author reply 554-5	6.1	2
34	Quality improvement in wellness reports in patients with Crohn's disease. <i>Accreditation and Quality Assurance</i> , <b>2006</b> , 11, 278-283	0.7	2



33	Effects of pure ethanol and alcopops on glucose, insulin, and the insulin-like growth factor system in healthy subjects. <i>Growth Hormone and IGF Research</i> , <b>2005</b> , 15, 243-50	2	6
32	Omega-3 fatty acids inhibit an increase of proinflammatory cytokines in patients with active Crohn's disease compared with omega-6 fatty acids. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2005</b> , 22, 1121-8	6.1	42
31	Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn's disease and ulcerative colitis. <i>BMC Gastroenterology</i> , <b>2005</b> , 5, 31	3	13
30	Insulin-like growth factors (IGFs) and IGF binding proteins in active Crohn's disease treated with omega-3 or omega-6 fatty acids and corticosteroids. <i>Scandinavian Journal of Gastroenterology</i> , <b>2005</b> , 40, 1214-21	2.4	21
29	The insulin-like growth factor system and markers of inflammation in adult patients with inflammatory bowel disease. <i>Hormone Research in Paediatrics</i> , <b>2005</b> , 64, 9-15	3.3	33
28	Budd-Chiari and inferior caval vein syndromes due to membranous obstruction of the liver veins: successful treatment with angioplasty and transcaval transjugular intrahepatic porto-systemic shunt. <i>Scandinavian Journal of Gastroenterology</i> , <b>2004</b> , 39, 1025-8	2.4	7
27	The influence of amphotericin B and neomycin on the effect of human relaxin-2 on foetal membranes and isolated myometrium. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2004</b> , 94, 144-50	3.1	1
26	Combined liver vein and spleen pulp pressure measurements in patients with portal or splenic vein thrombosis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2004</b> , 39, 594-9	2.4	13
25	Markers of fetal growth and serum levels of insulin-like growth factor (IGF) I, -II and IGF binding protein 3 in adults. <i>European Journal of Epidemiology</i> , <b>2004</b> , 19, 41-7	12.1	8
24	Serum insulin-like growth factors, insulin-like growth factor binding proteins, and breast cancer risk in postmenopausal women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2004</b> , 13, 1759-64	4	19
23	Effect of combination therapy with a calcium channel blocker and an angiotensin-converting enzyme inhibitor on renal hypertrophy and urinary albumin excretion in diabetic rats. <i>Experimental Diabetes Research</i> , <b>2003</b> , 4, 191-9		2
22	Albumin in vaginal fluid is a marker of infection in early pregnancy. <i>International Journal of Gynecology and Obstetrics</i> , <b>2003</b> , 83, 307-8	4	5
21	Effects of tamoxifen on insulin-like growth factors, IGF binding proteins and IGFBP-3 proteolysis in breast cancer patients. <i>Anticancer Research</i> , <b>2003</b> , 23, 2815-20	2.3	9
20	Inhibitory effects of octreotide on renal and glomerular growth in early experimental diabetes in mice. <i>Journal of Endocrinology</i> , <b>2002</b> , 172, 637-43	4.7	18
19	Effects of octreotide on serum insulin-like growth factor I and insulin-like growth factor binding proteins in patients with cirrhosis. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2002</b> , 62, 39-47	2	4
18	Low free and total insulinlike growth factor I (IGF-I) and IGF binding protein-3 levels in chronic inflammatory bowel disease: partial normalization during prednisolone treatment. <i>American Journal of Gastroenterology</i> , <b>2002</b> , 97, 673-678	0.7	12
17	Soluble CD163: a marker molecule for monocyte/macrophage activity in disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2002</b> , 237, 29-33	2	81
16	Development and Evaluation of an ELISA for Human Trefoil Factor 3. <i>Clinical Chemistry</i> , <b>2002</b> , 48, 1689-1695	3.5	46

15	Angiotensin converting enzyme inhibitor suppresses glomerular transforming growth factor beta receptor expression in experimental diabetes in rats. <i>Diabetologia</i> , <b>2001</b> , 44, 495-500	10.3	38
14	Effect of nitrendipine and nisoldipine on renal structure and function in long-term experimental diabetes in rats. <i>American Journal of Kidney Diseases</i> , <b>2000</b> , 36, 368-77	7.4	4
13	The calcium channel blocker nitrendipine attenuates renal and glomerular hypertrophy in diabetic rats. <i>Nephron Experimental Nephrology</i> , <b>1999</b> , 7, 242-50		10
12	Effect of the calcium channel blocker nitrendipine in normotensive and spontaneously hypertensive, diabetic rats on kidney morphology and urinary albumin excretion. <i>Journal of Hypertension</i> , <b>1999</b> , 17, 973-81	1.9	8
11	Effect of octreotide, captopril or insulin on renal changes and UAE in long-term experimental diabetes. <i>Kidney International</i> , <b>1998</b> , 53, 173-80	9.9	24
10	Effect of immunosuppression on kidney and serum insulin-like growth factor-I (IGF-I), IGF binding proteins, and renal growth following unilateral nephrectomy in rats. <i>Metabolism: Clinical and Experimental</i> , <b>1998</b> , 47, 817-23	12.7	8
9	Octreotide prevents the early increase in renal insulin-like growth factor binding protein 1 in streptozotocin diabetic rats. <i>Diabetes</i> , <b>1998</b> , 47, 924-30	0.9	21
8	Developmental changes in serum levels of free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit in rats. <i>Endocrinology</i> , <b>1998</b> , 139, 4286-92	4.8	38
7	Effects of growth hormone on steroid-induced increase in ability of urea synthesis and urea enzyme mRNA levels. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>1998</b> , 275, E79-86	6	9
6	Effect of octreotide and insulin on manifest renal and glomerular hypertrophy and urinary albumin excretion in long-term experimental diabetes in rats. <i>Diabetologia</i> , <b>1995</b> , 38, 135-44	10.3	14
5	Expression of insulin-like growth factor binding proteins in the rat kidney: effects of long-term diabetes. <i>Endocrinology</i> , <b>1995</b> , 136, 1835-42	4.8	67
4	The role of growth hormone, insulin-like growth factors (IGFs), and IGF-binding proteins in experimental diabetic kidney disease. <i>Metabolism: Clinical and Experimental</i> , <b>1995</b> , 44, 67-71	12.7	28
3	Increased ornithine decarboxylase activity in kidneys undergoing hypertrophy in experimental diabetes. <i>Molecular and Cellular Endocrinology</i> , <b>1992</b> , 86, 67-72	4.4	15
2	Selenium in the central nervous system of rats exposed to 75-Se L-selenomethionine and sodium selenite. <i>Biological Trace Element Research</i> , <b>1992</b> , 35, 119-27	4.5	15
1	Selenium complexes in the anterior pituitary of rats exposed to L-selenomethionine. <i>Vigiliae Christianae</i> , <b>1990</b> , 59, 291-6	0.2	